AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23880355 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of 5% energy intake from SFA with fructose
Number of subjects: 3496
Study 22641251 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (3-month treadmill exercise training)
Number of subjects: 61
Study 22641251 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=33)
Number of subjects: 61
Study 19494683 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximal sealants
Number of subjects: 0
Study 19494683 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride applications (including slow-release devices)
Number of subjects: 0
Study 19494683 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures to help remineralize demineralized tissue (including 3 different methods of delivering amorphous calcium phosphate)
Number of subjects: 0
Study 19494683 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures to help modify the biofilm (including ozone therapy and probiotics)
Number of subjects: 0
Study 19494683 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures to increase enamel resistance to demineralization (including laser treatment of enamel)
Number of subjects: 0
Study 19494683 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel 'hybrid' technique for treatment of primary molar caries (Hall technique)
Number of subjects: 0
Study 18085105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural and subarachnoid puncture using an introducer needle
Number of subjects: 224
Study 18085105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural and subarachnoid puncture without an introducer
Number of subjects: 224
Study 18085105 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid puncture with an introducer
Number of subjects: 224
Study 18085105 — intervention group
Group type: COMPARATOR
Intervention: Subarachnoid puncture with an introducer to within a few millimeters of the dural sac
Number of subjects: 224
Study 15193668 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive and explanatory information (AUT‐D + E)
Number of subjects: 576
Study 15193668 — intervention group
Group type: COMPARATOR
Intervention: Descriptive information alone (AUT‐D)
Number of subjects: 576
Study 15193668 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined information (AUT‐D + E)
Number of subjects: 576
Study 11772963 — intervention group
Group type: EXPERIMENTAL
Intervention: Biennial screening with Hemoccult‐II
Number of subjects: 30967
Study 11772963 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 30967
Study 11772963 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders (those who accepted the first screening but not subsequent ones)
Number of subjects: 30967
Study 9834808 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with intravenous piritramide (group P-PCA)
Number of subjects: 120
Study 9834808 — intervention group
Group type: COMPARATOR
Intervention: Nurse-administered bolus injections of piritramide (group P-Bolus)
Number of subjects: 120
Study 9834808 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with subarachnoid bupivacaine (group B-PCA)
Number of subjects: 120
Study 9834808 — intervention group
Group type: COMPARATOR
Intervention: Nurse-administered bolus injections of bupivacaine (group B-Bolus)
Number of subjects: 120
Study 8620675 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton (600mg every 6 hours for 8 days)
Number of subjects: 20
Study 2649324 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH (Protaphane)
Number of subjects: 82
Study 2649324 — intervention group
Group type: EXPERIMENTAL
Intervention: Lente (Monotard)
Number of subjects: 82
Study 582533 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31605294 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted counseling
Number of subjects: 1036
Study 31605294 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling according to national guidelines
Number of subjects: 1036
Study 31605294 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand counseling
Number of subjects: 1036
Study 31860172 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect intervention
Number of subjects: 110
Study 31860172 — intervention group
Group type: COMPARATOR
Intervention: Attention-control condition
Number of subjects: 110
Study 28276979 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted external stimulation (eyes closed + silence)
Number of subjects: 0
Study 28276979 — intervention group
Group type: COMPARATOR
Intervention: Non-restricted external stimulation (eyes open + ambient noise)
Number of subjects: 0
Study 28276979 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of visual stimulation
Number of subjects: 0
Study 28276979 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of auditory stimulation
Number of subjects: 0
Study 26439112 — intervention group
Group type: EXPERIMENTAL
Intervention: FL training group (forced left instruction)
Number of subjects: 26
Study 26439112 — intervention group
Group type: EXPERIMENTAL
Intervention: NF training group (non-forced instruction)
Number of subjects: 26
Study 23364953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg for 48 weeks followed by open-label TDF for an additional 192 weeks
Number of subjects: 641
Study 23364953 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) 10 mg for 48 weeks followed by open-label TDF for an additional 192 weeks
Number of subjects: 641
Study 23364953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 641
Study 23364953 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 641
Study 21295383 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower oil (SAF) 8 g daily for 16 weeks
Number of subjects: 55
Study 21295383 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 8 g daily for 16 weeks
Number of subjects: 55
Study 18823072 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 18823072 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (internal standard)
Number of subjects: 0
Study 17713595 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer presentation of images with spider-like characteristics, n = 13
Number of subjects: 25
Study 17713595 — intervention group
Group type: COMPARATOR
Intervention: Placebo group, n = 12
Number of subjects: 25
Study 17713595 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up study after 6 months, n = 25 (combined treatment and placebo)
Number of subjects: 25
Study 15887629 — intervention group
Group type: EXPERIMENTAL
Intervention: G 5.0 mg/M 400 mg
Number of subjects: 198
Study 15887629 — intervention group
Group type: COMPARATOR
Intervention: G 2.5 mg/M 400 mg
Number of subjects: 198
Study 15887629 — intervention group
Group type: EXPERIMENTAL
Intervention: G 5.0 mg/M 400 mg and G 2.5 mg/M 400 mg
Number of subjects: 198
Study 10904994 — intervention group
Group type: EXPERIMENTAL
Intervention: Madden operation + tamoxifen 20 mg OD
Number of subjects: 121
Study 10904994 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumorectomy to disease free margins + tamoxifen 20 mg OD
Number of subjects: 121
Study 9287060 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical water and systemic doxycycline, 100 mg for 2 weeks
Number of subjects: 113
Study 9287060 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.12% chlorhexidine (CHX) and systemic doxycycline, 100 mg for 2 weeks
Number of subjects: 113
Study 9287060 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical povidone‐iodine and systemic doxycycline, 100 mg for 2 weeks
Number of subjects: 113
Study 9287060 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.12% CHX and placebo
Number of subjects: 113
Study 9287060 — intervention group
Group type: COMPARATOR
Intervention: Topical water and placebo
Number of subjects: 113
Study 8212751 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 0
Study 8212751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3607094 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental splint and physiotherapy program
Number of subjects: 21
Study 3607094 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation program (progressive muscle relaxation, biofeedback, stress management)
Number of subjects: 21
Study 3607094 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal treatment program (transcutaneous electrical nerve stimulation)
Number of subjects: 21
Study 30026154 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting after stent deployment
Number of subjects: 210
Study 30026154 — intervention group
Group type: COMPARATOR
Intervention: Nonwaiting group
Number of subjects: 210
Study 27154411 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure prior to inoculation with live attenuated influenza virus (LAIV)
Number of subjects: 0
Study 27154411 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) exposure
Number of subjects: 0
Study 27154411 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro exposure to DE particles
Number of subjects: 0
Study 23796162 — intervention group
Group type: EXPERIMENTAL
Intervention: Women Be Healthy 2 (modified intervention)
Number of subjects: 198
Study 23796162 — intervention group
Group type: COMPARATOR
Intervention: Women Be Healthy (original intervention)
Number of subjects: 198
Study 23796162 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 198
Study 22594302 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-to-moderate alcohol exposure in utero
Number of subjects: 20
Study 22594302 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alcohol exposure)
Number of subjects: 20
Study 20920772 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human C1-inhibitor (rhC1INH) at 100 U/kg
Number of subjects: 70
Study 20920772 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human C1-inhibitor (rhC1INH) at 50 U/kg
Number of subjects: 70
Study 20920772 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 70
Study 18756443 — intervention group
Group type: COMPARATOR
Intervention: Early activation (1-2 months post-implant use)
Number of subjects: 0
Study 18756443 — intervention group
Group type: EXPERIMENTAL
Intervention: Late activation (1 year post-implant use)
Number of subjects: 0
Study 18756443 — intervention group
Group type: COMPARATOR
Intervention: Control (prior to initial implant activation)
Number of subjects: 0
Study 11916780 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine infusion at a rate of 8 microg x kg(‐1) x min(‐1) (Group A)
Number of subjects: 16
Study 11916780 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 16
Study 9699223 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioprim tablets (80 mg of trimethoprim/400 mg sulfamethoxazole)
Number of subjects: 12
Study 9699223 — intervention group
Group type: COMPARATOR
Intervention: Bactrim tablets (80 mg of trimethoprim/400 mg sulfamethoxazole)
Number of subjects: 12
Study 7521788 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg/m2 cyclophosphamide (CHOP)
Number of subjects: 27
Study 7521788 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg/m2 cyclophosphamide (CHOP)
Number of subjects: 27
Study 7521788 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg/m2 cyclophosphamide (CHOP)
Number of subjects: 27
Study 2777436 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric (ECC) torque
Number of subjects: 20
Study 2777436 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric (CONC) torque
Number of subjects: 20
Study 2777436 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric H/Q quotient
Number of subjects: 20
Study 2777436 — intervention group
Group type: EXPERIMENTAL
Intervention: H/Q quotients not corrected for GET (CONC)
Number of subjects: 20
Study 2777436 — intervention group
Group type: EXPERIMENTAL
Intervention: H/Q quotients not corrected for GET (ECC)
Number of subjects: 20
Study 4139900 — intervention group
Group type: EXPERIMENTAL
Intervention: Split course radiotherapy
Number of subjects: 0
Study 4139900 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifications in treatment planning
Number of subjects: 0
Study 4139900 — intervention group
Group type: EXPERIMENTAL
Intervention: Large initial fractions and rest period
Number of subjects: 0
Study 30980316 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 30980316 — intervention group
Group type: COMPARATOR
Intervention: Censored surrogate outcome methods
Number of subjects: 0
Study 27999170 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial valve treatment
Number of subjects: 31
Study 25256248 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum protein profiling using SELDI‐TOF MS
Number of subjects: 66
Study 25256248 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree model of biomarkers
Number of subjects: 66
Study 23571450 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral plasma kinetic enucleation of prostate (TUPKEP)
Number of subjects: 60
Study 23571450 — intervention group
Group type: COMPARATOR
Intervention: Transurethral plasma kinetic resection of prostate (TUPKRP)
Number of subjects: 60
Study 21161733 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention
Number of subjects: 0
Study 21161733 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19442975 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 288
Study 19442975 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 288
Study 19442975 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (SDS-BMI reduction >0.5)
Number of subjects: 288
Study 17116939 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA combined with three daunorubicin (DNR) plus AraC courses and a 2‐year maintenance regimen (AraC group)
Number of subjects: 340
Study 17116939 — intervention group
Group type: COMPARATOR
Intervention: No AraC (no AraC group)
Number of subjects: 340
Study 15361277 — intervention group
Group type: EXPERIMENTAL
Intervention: HICA (high iron and calcium)
Number of subjects: 12
Study 15361277 — intervention group
Group type: COMPARATOR
Intervention: LI (low iron)
Number of subjects: 12
Study 11289747 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy as part of breast-conserving treatment (BCT) for DCIS
Number of subjects: 1010
Study 11289747 — intervention group
Group type: COMPARATOR
Intervention: Breast-conserving treatment (BCT) for DCIS without specific mention of control
Number of subjects: 1010
Study 9226731 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) technique
Number of subjects: 0
Study 9226731 — intervention group
Group type: COMPARATOR
Intervention: Stress education control condition
Number of subjects: 0
Study 8431342 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 20 micrograms kg‐1 and propofol 2.5 mg kg‐1
Number of subjects: 60
Study 8431342 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2.5 mg kg‐1
Number of subjects: 60
Study 2441836 — intervention group
Group type: EXPERIMENTAL
Intervention: CABO (cisplatin, methotrexate, bleomycin, and vincristine)
Number of subjects: 185
Study 2441836 — intervention group
Group type: COMPARATOR
Intervention: ABO (methotrexate, bleomycin, and vincristine)
Number of subjects: 185
Study 2441836 — intervention group
Group type: EXPERIMENTAL
Intervention: CABO
Number of subjects: 185
Study 2441836 — intervention group
Group type: COMPARATOR
Intervention: ABO
Number of subjects: 185
Study 29671256 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 93
Study 29671256 — intervention group
Group type: COMPARATOR
Intervention: Routine exogenous administration of estrogens
Number of subjects: 93
Study 28267365 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg E4
Number of subjects: 49
Study 28267365 — intervention group
Group type: COMPARATOR
Intervention: 2 mg estradiol valerate (E2V)
Number of subjects: 49
Study 28267365 — intervention group
Group type: EXPERIMENTAL
Intervention: 10, 20, or 40 mg E4
Number of subjects: 49
Study 26259892 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 0
Study 26259892 — intervention group
Group type: COMPARATOR
Intervention: Standard method with reduced calorie intake and increased physical activity
Number of subjects: 0
Study 24011606 — intervention group
Group type: EXPERIMENTAL
Intervention: strategy-oriented neuropsychological rehabilitation (60-minute sessions once a week for thirteen consecutive weeks)
Number of subjects: 102
Study 24011606 — intervention group
Group type: COMPARATOR
Intervention: control group (no intervention)
Number of subjects: 102
Study 20214694 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient (OP) treatment
Number of subjects: 59
Study 20214694 — intervention group
Group type: COMPARATOR
Intervention: Inpatient (IP) treatment
Number of subjects: 59
Study 19787599 — intervention group
Group type: EXPERIMENTAL
Intervention: dorzolamide/timolol (DTFC)
Number of subjects: 30
Study 19787599 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost/timolol (LTFC)
Number of subjects: 30
Study 16707588 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 669
Study 16707588 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 669
Study 15025759 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) administered at a constant low dose for up to 6 days
Number of subjects: 207
Study 15025759 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 207
Study 11687991 — intervention group
Group type: EXPERIMENTAL
Intervention: Trillium Biopassive Surface-coated oxygenator
Number of subjects: 30
Study 11687991 — intervention group
Group type: COMPARATOR
Intervention: Uncoated oxygenator
Number of subjects: 30
Study 9142028 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mL of albumin 5%
Number of subjects: 18
Study 9142028 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mL of Ringer's solution
Number of subjects: 18
Study 9142028 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mL of Ringer's acetate solution
Number of subjects: 18
Study 9142028 — intervention group
Group type: COMPARATOR
Intervention: 900 mL blood withdrawal
Number of subjects: 18
Study 8359178 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 10 mg cisapride regimen
Number of subjects: 17
Study 8359178 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 20 mg cisapride regimen
Number of subjects: 17
Study 8359178 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 10 mg cisapride regimen
Number of subjects: 17
Study 8359178 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of cisapride after 2 x 10 mg
Number of subjects: 17
Study 8359178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride plasma concentrations greater than 60 ng.ml‐1
Number of subjects: 17
Study 2820157 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 g/die supplementary mackerel diet, no physical training
Number of subjects: 49
Study 2820157 — intervention group
Group type: COMPARATOR
Intervention: Reducing diet (5,000 kJ/d), no mackerel diet, no physical training
Number of subjects: 49
Study 2820157 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing diet and a proportion of mackerels of 125 g/d, no physical training
Number of subjects: 49
Study 2820157 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing diet and mackerel diet 125 g/d as well as daily swimming training (20 to 30 min)
Number of subjects: 49
Study 30569953 — intervention group
Group type: EXPERIMENTAL
Intervention: Colored eye drops
Number of subjects: 34
Study 30569953 — intervention group
Group type: COMPARATOR
Intervention: Transparent eye drops
Number of subjects: 34
Study 27798335 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplements (MMNs)
Number of subjects: 4436
Study 27798335 — intervention group
Group type: COMPARATOR
Intervention: Fe60F (60 mg Fe and 400 μg folic acid)
Number of subjects: 4436
Study 27798335 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe30F (30 mg Fe and 400 μg folic acid)
Number of subjects: 4436
Study 25265895 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI GSK961081 400 µg + oral placebo
Number of subjects: 41
Study 25265895 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI GSK961081 1,200 µg + oral placebo
Number of subjects: 41
Study 25265895 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI GSK961081 400 µg + oral propranolol 80 mg
Number of subjects: 41
Study 25265895 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI GSK961081 1,200 µg + oral propranolol 80 mg
Number of subjects: 41
Study 25265895 — intervention group
Group type: COMPARATOR
Intervention: DPI and oral placebo
Number of subjects: 41
Study 22858074 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combined isosorbide dinitrate/hydralazine (FDC I/H)
Number of subjects: 0
Study 21094356 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD for primary prevention
Number of subjects: 424
Study 18678838 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gene assay
Number of subjects: 465
Study 16583285 — intervention group
Group type: EXPERIMENTAL
Intervention: Committee-reviewed integrated examinations (2001-2002)
Number of subjects: 520
Study 16583285 — intervention group
Group type: EXPERIMENTAL
Intervention: Committee-reviewed integrated examinations (2002-2003)
Number of subjects: 520
Study 16583285 — intervention group
Group type: COMPARATOR
Intervention: Departmentally/discipline based examinations (2000-2001)
Number of subjects: 520
Study 14557961 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500-1000 mg), Ethambutol (25 mg/kg), Rifampin (600 mg) 3 times per week
Number of subjects: 18
Study 10892533 — intervention group
Group type: COMPARATOR
Intervention: Flyer about a worksite dietary intervention
Number of subjects: 561
Study 10892533 — intervention group
Group type: EXPERIMENTAL
Intervention: Flyer plus personalized hand-signed letter with general population heart disease risk statistics
Number of subjects: 561
Study 10892533 — intervention group
Group type: EXPERIMENTAL
Intervention: Flyer plus personalized hand-signed letter with Hispanic heart disease risk statistics
Number of subjects: 561